© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Septerna, Inc. (SEPN) stock declined over -0.34%, trading at $26.04 on NASDAQ, down from the previous close of $26.13. The stock opened at $25.95, fluctuating between $25.75 and $26.65 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 17, 2026 | 25.50 | 26.57 | 24.84 | 26.13 | 390.34K |
| Apr 16, 2026 | 25.92 | 26.85 | 24.98 | 24.99 | 352.2K |
| Apr 14, 2026 | 23.57 | 24.40 | 23.35 | 24.13 | 213.43K |
| Apr 13, 2026 | 23.00 | 24.33 | 22.83 | 23.34 | 218.21K |
| Apr 10, 2026 | 24.92 | 24.92 | 22.97 | 23.09 | 629.07K |
| Apr 09, 2026 | 24.40 | 25.22 | 24.18 | 24.83 | 207.7K |
| Apr 08, 2026 | 25.71 | 25.83 | 24.22 | 24.49 | 162.06K |
| Apr 07, 2026 | 24.67 | 24.89 | 24.05 | 24.84 | 189.55K |
| Apr 06, 2026 | 24.88 | 25.48 | 24.38 | 24.78 | 140.16K |
| Apr 02, 2026 | 23.90 | 25.29 | 23.90 | 25.18 | 288.09K |
| Apr 01, 2026 | 24.33 | 24.94 | 24.18 | 24.37 | 210.24K |
| Mar 31, 2026 | 23.74 | 24.86 | 23.50 | 24.03 | 257.75K |
| Mar 30, 2026 | 23.95 | 24.17 | 22.89 | 23.30 | 223.28K |
| Mar 27, 2026 | 24.68 | 25.16 | 23.75 | 23.87 | 144.59K |
| Mar 25, 2026 | 23.50 | 25.08 | 23.50 | 24.21 | 131.92K |
| Mar 24, 2026 | 23.77 | 23.92 | 22.97 | 23.44 | 164.46K |
| Mar 23, 2026 | 24.63 | 25.33 | 23.57 | 23.78 | 242.91K |
| Mar 20, 2026 | 24.26 | 24.51 | 23.82 | 24.18 | 479.78K |
| Mar 19, 2026 | 23.83 | 24.57 | 23.35 | 24.28 | 279.59K |
| Mar 18, 2026 | 25.10 | 25.35 | 24.04 | 24.11 | 232.08K |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
| Employees | 75 |
| Beta | 3.46 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |